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Chitinase inhibitors have chemotherapeutic potential
as fungicides, pesticides, andantiasthmatics.Argifin,
a natural product cyclopentapeptide, competitively
inhibits family 18 chitinases in the nanomolar to mi-
cromolar range and shows extensive substrate mim-
icry. In an attempt tomap the active fragments of this
large natural product, the cyclopentapeptide was
progressively dissected down to four linear peptides
and dimethylguanylurea, synthesized using a combi-
nation of solution and solid phase peptide synthesis.
The peptide fragments inhibit chitinase B1 from
Aspergillus fumigatus (AfChiB1), the human chitotrio-
sidase, and chitinase activity in lung homogenates
fromamurinemodel of chronicasthma,withpotencies
ranging fromhighnanomolar tohighmicromolar inhibi-
tion. X-ray crystallographic analysis of the chitinase-
inhibitor complexes revealed that the conformations
of the linear peptides were remarkably similar to that
of the natural product. Strikingly, the dimethylguanyl-
urea fragment, representing only a quarter of the natu-
ral product mass, was found to harbor all significant
interactions with the protein and binds with unusually
high efficiency. The data provide useful information
that could lead to the generation of drug-like, natural
product-based chitinase inhibitors.
INTRODUCTION
Natural products and compounds directly derived from them
continue to play a significant role in modern drug discovery
and development (Newman and Cragg, 2007). The most effec-
tive compounds targeting chitinases, the enzymes that catalyze
the hydrolysis of b(1,4)-linked N-acetylglucosamine (chitin), are
natural products (reviewed in Andersen et al., 2005). Chitin is
an important structural component of the cell wall of fungi (Munro
and Gow, 2001), the microfilarial sheath in parasitic nematodes
(Harris et al., 2000) as well as the cuticles of insects (Merzendor-
fer, 2006). Although chitin is absent frommammalian physiology,
fungi, nematodes, and insects must all metabolize chitin at im-
portant stages of their life cycle; hence, small-molecule chitinase
inhibitors have the potential to act as biocontrol agents in bothChemistry & Biologymedicine and agriculture. Several natural product chitinase in-
hibitors have indeed been shown to exhibit interesting biological
activities. For example, the pseudotrisaccharide allosamidin, the
most extensively studied and generally themost potent chitinase
inhibitor, has been shown to inhibit cell separation in fungi (Kur-
anda and Robbins, 1991; Sakuda et al., 1990), blockmalaria par-
asite penetration into themosquito midgut (Tsai et al., 2001), and
inhibit insect larvae development (Sakuda, 1996). Additionally,
this compound was shown to decrease the number of inflamma-
tory cells in a mouse model of asthma by targeting the acidic
mammalian chitinase (AMCase) (Zhu et al., 2004). Although total
syntheses of allosamidin have been reported (Berecibar et al.,
1999), the length and complexity of the synthetic routes involved
severely limit both the availability of this compound and the
scope for structure-based design of novel allosamidin-derived
inhibitors.
Recently, there has been considerable interest in the ability of
peptides to mimic carbohydrate-protein interactions and bind to
enzymes and lectins (e.g., Johnson and Pinto, 2002; Vyas et al.,
2003; Dharmasena et al., 2007). Synthetic compounds that can
mimic such peptide ligands, i.e., peptidomimetics, could provide
potential drug candidates with improved stability toward proteo-
lytic breakdown but retaining high potency. Two classes of
peptide-based chitinase inhibitors are known: the cyclic pro-
line-containing dipeptides isolated from broth of a marine bacte-
rium (Izumida et al., 1996a) and the cyclic pentapeptides argadin
and argifin secreted from fungal strains (Omura et al., 2000; Arai
et al., 2000). The synthesis of the natural product cyclo-(L-Arg-D-
Pro), or CI-4, is straightforward (Izumida et al., 1996b; Houston
et al., 2002a) and in principle further analogs are readily available
by substitution of either amino acid residue. However, although
several cyclic dipeptide derivatives have been synthesized, their
chitinase inhibition is moderate (high micromolar range) (Hous-
ton et al., 2002a, 2004). The total syntheses of both argadin
and argifin have been achieved (Dixon et al., 2005, 2006) using
a combination of solid phase and solution chemistry. For argifin
(1, Figure 1A), IC50 values of 27 nM (Dixon et al., 2005), 33 mM
(Houston et al., 2002b), and 4.5 mM (Rao et al., 2005c) have
been determined for chitinase B1 from Aspergillus fumigatus
(AfChiB1), chitinase B from Serratia marcescens, and human
chitotriosidase (hCHT), respectively. However, although argifin
is a potent chitinase inhibitor, its molecular weight and number
of hydrogen-bond donors/acceptors well exceed the Lipinski
criteria for drug-likeliness (Lipinski, 2000), while its peptide-
based framework is also likely to be prone to proteolytic
degradation.15, 295–301, March 2008 ª2008 Elsevier Ltd All rights reserved 295
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Structural Dissection of ArgifinFigure 1. Structures and Activities of Argifin-Derived Peptides
(A) Chemical structures.
(B) Dose-response curves for the linear peptides against AfChiB1. Chitinase activity represented by relative fluorescence is shown as a function of inhibitor con-
centration for the argifin-derived peptides. Dose-response curves were fitted with GraFit (Leatherbarrow, 2001) and resulting IC50 values are reported in Table 1.Here, we use the available AfChiB1-argifin complex crystal
structure to design linearized fragments of this natural product
cyclopentapeptide. Using a combination of X-ray crystallo-
graphic analysis of the peptide-protein complexes and enzymol-
ogy, we show that these argifin fragments maintain their binding
mode to the enzyme and continue to inhibit potently. Surpris-
ingly, the (tiny) dimethylguanylurea fragment appears to be re-
sponsible for formingmost of the key interactions and represents
an unusually efficient binder and an attractive starting point for
structure-based optimization.
RESULTS AND DISCUSSION
Design and Synthesis of Linear Peptide Inhibitors
The natural product argifin 1 (Figure 1A) is a potent inhibitor of
several family 18 chitinases, acting through extensive (peptide)
mimicry of the natural carbohydrate substrate (Figure 2; Houston
et al., 2002b; Rao et al., 2005b). The structure of the compound
in complex with chitinase B from A. fumigatus (Rao et al., 2005b;
Figure 2) was used as a basis to design a range of peptide frag-
ments that all contain the dimethylguanylurea group previously
shown to deeply penetrate the active site pocket (Houston
et al., 2002b; Rao et al., 2005b; Figure 2). Hence, the linear
tetra-, tri-, and dipeptides 2–4 were generated (Figure 1), along
with an isolated Arg derivative 5 with an N-methylcarbamoyl-
derivatized side chain, and the dimethylguanylurea 6 itself
(Figure 1).
For the preparation of 2–4, Arg-containing di-, tri-, and tetra-
peptide precursors were assembled by manual Fmoc SPPS on
2-chlorotrityl chloride polystyrene resin. After cleavage from
the resin and side chain deprotection, the Arg(MC) modification
was introduced by acylation with MeNHCO2Su/DBU/DMF at
40C, as described for the synthesis of argifin. 2–4 were isolated
by preparative HPLC and were fully characterized by NMR and
high resolution mass spectrometry. 5 was prepared from296 Chemistry & Biology 15, 295–301, March 2008 ª2008 Elsevier LFmoc-L-Arg(Pmc)-OH by standard solution chemistry, but using
methyl isocyanate to install the Arg(MC) modification, and was
isolated by preparative HPLC and characterized as previously.
6 was prepared from methylguanidine hydrochloride by neutral-
izationwith ion exchange resin (Dowex hydroxide form), followed
by treatment with methyl isocyanate and isolation as for 5. Full
details of the syntheses are available in the Supplemental Data
available with this article online.
Investigation of Inhibition and Binding Mode
of the Argifin Peptide Fragments
Argifin has been shown to be a competitive inhibitor of family 18
chitinases, binding with affinities from in the nanomolar to micro-
molar range (Arai et al., 2000; Houston et al., 2002b; Rao et al.,
2005b). To compare the linear peptides synthesized in this study,
inhibition was tested against a fungal chitinase (AfChiB1), the
human chitotriosidase (hCHT), and total chitinase activity from
a lung homogenate (LH) from a mouse model of chronic asthma.
This lung homogenate has previously been shown tomainly con-
tain the acidic mammalian chitinase (AMCase) that has recently
been proposed as an antiasthma drug target (McMillan and
Lloyd, 2004; Zhu et al., 2004; Schu¨ttelkopf et al., 2006; Table 1).
In parallel, AfChiB1 crystals were soaked in solutions containing
compounds 2–6 and the resulting crystal structures investigated.
The five structures were solved to amaximum resolution of 1.90–
2.2 A˚ (Table 2), similar to the published (2.0 A˚) AfChiB1-argifin
complex, and thus the structures possess a comparable amount
of solvent detail. The data yielded electron densitymaps showing
clear positions for the ligand, confirming the structure and stereo-
chemistry of the synthesized linear peptides (Figure 2).
Argifin itself binds to family 18 chitinases through subsites (i.e.,
where the individual sugars of the chitin polymer are known to
bind) 1, +1, and +2 of the active site, following standard glyco-
side hydrolase subsite nomenclature (Davies et al., 1997), with
hydrolysis taking place between the 1 and +1 sugar. In thetd All rights reserved
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Structural Dissection of ArgifinFigure 2. AfChiB1-Inhibitor Complex Crystal Structures
Active sites are shown for AfChiB1 in complex with the argifin-derived peptides alongside the published AfChiB1-argifin complex (PDB code: 1W9V; Rao et al.,
2005b). The AfChiB1 backbone is shown as a gray ribbon. Side chains lining the inhibitor binding site are shown as sticks with gray carbons and labeled. Dual
conformations of Trp137 and Asp175 are shown for the dipeptide and dimethylguanylurea complexes, respectively. The inhibitor molecules are shown as stick
models with magenta carbon atoms. Water molecules involved in water-mediated protein-inhibitor interactions are shown as orange spheres. Hydrogen bonds
are shown as dotted green lines. Unbiased jFo j  jFc j, fcalc electron density maps are shown at 2.5s for the linear peptide complexes. The position of a chito-
pentaose oligosaccharide as observed in a previously trapped chitinase-substrate complex (van Aalten et al., 2001) is shown as transparent sticks with yellow
carbon atoms, superimposed on the AfChiB1-argifin complex.previously published AfChiB1-argifin crystal structure (Figure 2),
all inhibitor peptide bonds are in the trans configuration except
for the cis L-Arg to N-MePhe bond (Rao et al., 2005b). The
N-methyl carbamoyl nitrogen hydrogen bonds to the side chain
of Asp175, whereas its oxygen forms a hydrogen bond to the
hydroxyl group of Tyr245. The arginine guanidinium group forms
two hydrogen bonds with Glu177 (the catalytic acid) and one
with the side chain of Asp246. Additionally, the first isoAsp
side chain generates a hydrogen bond with the Trp137 side
chain, and the argifin arginine carbonyl forms two hydrogen
bonds with the Arg301 side chain. One intramolecular hydrogen
bond is observed between the first isoAsp backbone N and the
D-Ala carbonyl O, associated with a b-turn centered on the
L-Arg-L-MePhe dipeptide moiety (Figure 2). Numerous water-
mediated hydrogen bonds are observed involving Arg301,
Glu322, and Asn323. The side chains of Tyr48, Met243, and
Trp384 generate hydrophobic interactions and surround the
N-methyl carbamoyl group, whereas the side chains of Trp137
and Phe251 form extensive stacking interactions with the argifin
L-Phe. Almost all of these residues are highly conserved in familyChemistry & Biology 118 chitinases, explaining the potency of this inhibitor reported for
several enzymes.
Argifin Linearization and Truncation Generates
an Active Tetrapeptide
Linearization of the cyclopentapeptide argifin 1 by removal of
one of the Asp residues results in tetrapeptide 2 and surprisingly
leads to retention of significant inhibitory activity (IC50 = 4.3 mM
against AfChiB, Table 1). In agreement with this, the crystal
structure (Figure 2) reveals that it binds the chitinase with the
Arg(MC) side chain in an identical position to that observed in
the AfChiB1-argifin complex, with a similar conformation of the
peptide backbone (shifts up to 0.6 A˚ for equivalent argifin back-
bone atoms). Hence, the inhibitor fills the 1, +1, and +2 sub-
sites, and all direct hydrogen bonds and intramolecular hydro-
gen bonds observed in the argifin complex are conserved
(Figure 2). The only significant differences are the loss of water-
mediated hydrogen bonds to Glu322/Asn323 and a cis amide
bond in the N-terminal N-acetyl group, allowing an additional in-
ternal hydrogen bond between the C-terminal carboxylate and5, 295–301, March 2008 ª2008 Elsevier Ltd All rights reserved 297
Chemistry & Biology
Structural Dissection of ArgifinTable 1. Chitinase Inhibition of Argifin-Derived Peptides
AfChiB1 IC50 AfChiB1 BEI hCHT IC50 LH IC50
Argifin 0.027 11.7 4.5 0.0300.003
Tetrapeptide 4.3±0.2 9.1 282 2.90.2
Tripeptide 5.1±0.2 10.2 684 8.20.5
Dipeptide 12±1 12.0 19030 272
Monopeptide 81±4 15.3 1000100 18020
Dimethylguanylurea 500±20 27.7 5800400 103040
IC50 values of argifin and the peptide derivatives against AfChiB1, hCHT, andmouse lung homogenate (LH) are given inmicromolar. Argifin inhibition of
AfChiB1 and hCHT have been reported previously (Rao et al., 2005b; Dixon et al., 2005). For AfChiB1, ligand efficiency is expressed as the Binding
Efficiency Index (Abad-Zapatero and Metz, 2005), BEI =log(Ki)/M, with M being the mass in kilodaltons and Kis derived from the IC50 data using the
Cheng and Prusoff equation.the backbone nitrogen of D-Ala (Figure 2). The total surface area
buried by argifin and 2 are identical (141 A˚2). Thus, it seems likely
that removal of the second isoAsp and linearization of the natural
product lowers the affinity of binding to the chitinases through
entropic penalties incurred upon complexation of the more flex-
ible, acyclic structure of 2 and/or loss of several water-mediated
hydrogen bonds.
Further Truncation of the Tetrapeptide
Generates an Active Tripeptide
It is apparent from the AfChiB-argifin/tetrapeptide complexes
that the D-Ala side chain does not make significant interactions
with the enzyme active site (Figure 2). Indeed, the tripeptide 3,
lacking the D-Ala residue, inhibits chitinase activity of AfChiB1,
hCHT, and LH with IC50 values similar to those of the tetrapep-
tide 2 (Figure 1B; Table 1). Again, crystallographic analysis of
a complex with AfChiB (Figure 2) shows that the Arg(MC) side
chain binds in its usual position and that the tripeptide backbone
adopts a conformation almost identical to that observed in the
AfChiB1-argifin complex (shifts up to 0.5 A˚ for equivalent argifin
backbone atoms). The differences from the tetrapeptide are the
displacement of the isoAsp C terminus, the loss of the extra in-
ternal hydrogen bond, and an extra water-mediated hydrogen
bond with Ser250.
An Argifin Dipeptide Fragment Showing
Micromolar Inhibition
To further narrow down the pharmacophore of the argifin natural
product, the tripeptide-protein interactions of 3 were evaluated
for the individual amino acids to design the most potent dipep-
tide. Both the derivatized argifin and the N-methylated phenylal-
anine make tight interactions with the active site (Figure 2) and
truncation of these amino acids was expected to significantly
compromise binding. The only interaction the remaining isoAsp
side chain makes with the protein is to accept a hydrogen bond
from the Trp137 indole, although this interaction is fully con-
served in the argifin, tetrapeptide and tripeptide complexes,
andmutation of the tryptophan is known tocompletely abolish ar-
gifin inhibition (Rao et al., 2005b; Figure 2). Nevertheless, it was
decided to synthesize dipeptide 4, which inhibits the chitinases
with IC50 values less thananorder ofmagnitudehigher than those
measured for the tri/tetrapeptides 2 and 3 (Figure 1B; Table 1).
The AfChiB1-dipeptide complex (Figure 2) reveals that the termi-
nal Arg(MC)moiety generates the samefive hydrogen bondswith298 Chemistry & Biology 15, 295–301, March 2008 ª2008 Elsevier LAsp175, Glu177, Tyr245, and Asp246 as seen in the AfChiB1
complexeswith argifin. However, the loss of an internal hydrogen
bond and the hydrogen bond with the side chain of Trp137
appears to induce significant conformational changes in the
backbone (shifts up to 3.4 A˚ for equivalent argifin backbone
atoms), with the L-Arg-N-methyl-L-Phe peptide bond adopting
a trans configuration (Figure 2). Consequently, the Arg301 to
L-Arg carbonyl hydrogen bond is replaced with a hydrogen
bond from Arg301 to the MePhe carboxylate, and the MePhe
side chain is displaced to only partially occupy the +2 subsite
through a reduced interaction with Phe251 (Figure 2). The shift
of the inhibitor backbone also causes Trp137 to settle in a dual
conformation, with an additional conformation pointing toward
the indole group of Trp384, which itself is also displaced. How-
ever, these conformational changes also result in the generation
of three new water-mediated hydrogen bonds that may partially
compensate for the loss of direct hydrogen bonds. In addition,
the considerably smaller dipeptide generates a protein contact
surface of equivalent size to that observed in theAfChiB1-tripep-
tide complex (Table 2).
The N-Methylcarbamoylated Arginine
Is the Pharmacophoric Argifin Amino Acid
Despite the linearizationand truncationof argifindown toadipep-
tide, significant activity is retainedand thepharmacophore is thus
likely to be an even smaller fragment. We next investigated the
activity of the acetylated single amino acid, ‘‘monopeptide’’ 5.
Strikingly, this monopeptide still inhibits AfChiB1 with an IC50
valueof 81mM(Figure 2; Table 1), although this is 3orders ofmag-
nitude higher than inhibition by the intact cyclopentapeptide 1
and 40-fold higher than the linear tetrapeptide 2. The crystal
structure of the AfChiB-monopeptide complex shows that
despite the removal of the MePhe residue and concomitant
loss of the hydrophobic interactions with Trp137/Phe 251, the
modified arginine side chain still establishes the same five hydro-
genbondsasobserved in theargifin complex (Figure 2). Similar to
the dipeptide complex, Trp137 is flipped with a 120 rotation
around the Ca-Cb bond, allowing stacking interactions with the
L-Arg backbone and the N-terminal acetyl group.
Dimethylguanylurea Is an Active Chitinase
Inhibitor Fragment
Because the terminal atoms of the modified arginine residue of
1–5 appear to make the majority of the interactions with thetd All rights reserved
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Structural Dissection of ArgifinTable 2. Summary of Data Collection, Structure Refinement, and Analysis
Tetrapeptide Tripeptide Dipeptide Monopeptide Dimethylguanylurea
Resolution (A˚) 201.95 (2.021.95) 202.05 (2.122.05) 202.00 (2.072.00) 201.90 (1.971.90) 202.20 (2.282.20)
Unit cell (A˚) a = b = 117.06 a = b = 117.42 a = b = 117.07 A = b = 117.18 a = b = 117.77
c = 99.75 c = 99.54 c = 99.95 C = 100.05 c = 99.57
# Unique reflections 95975 (9051) 84294 (8096) 89613 (8652) 105305 (10382) 67434 (6511)
Multiplicity 3.7 (3.2) 3.7 (2.8) 3.6 (3.3) 3.3 (3.2) 3.2 (2.8)
Rmerge (%) 9.2 (42.7) 11.3 (37.7) 10.6 (49.1) 8.4 (42.0) 7.9 (49.2)
I/sI 17.2 (2.5) 14.3 (2.7) 16.2 (2.5) 17.5 (2.5) 15.2 (2.1)
Completeness (%) 98.0 (92.7) 99.6 (95.8) 98.6 (96.0) 99.1 (98.3) 97.9 (95.6)
# atoms in refinement 7141 7189 7100 7238 6776
# solvent molecules 842 910 827 1002 552
R, Rfree (%) 17.6, 19.7 17.2, 19.5 17.7, 21.5 16.6, 18.7 18.7, 22.0
<B > protein (A˚2) 24 20 26 23 30
<B > ligand (A˚2) 41 46 49 31 50
R.m.s.d. from
ideal geometry
Bond lengths (A˚) 0.011 0.011 0.011 0.012 0.011
Bond angles () 1.53 1.53 1.57 1.54 1.54
Inhibitor-buried area (A˚2) 141 127 123 97 59
Values for the highest resolution shell are given in brackets.protein, we decided to investigate inhibition of the dimethylgua-
nylurea 6 itself. Strikingly, this small fragment, consisting of only
9 heavy atoms and with a molecular weight of 130 Da, still shows
detectable inhibition of AfChiB1 (IC50 = 500 mM) and other chiti-
nases (Figure 1B; Table 1). In the dimethyl-guanylurea complex
crystal structure with AfChiB1, the fragment is well ordered, oc-
cupies the same position as observed in the argifin and linear
peptide complexes, and is able to make five hydrogen bonds
(Figure 2). The reduction in potency compared to the monopep-
tide can be explained by the loss of the L-Arg carbonyl to Arg301
hydrogen bond as well as a considerably smaller buried surface
area (Table 2) due to loss of interactions with Trp137 (Figure 2).
Concluding Remarks
In order to establish the minimum elements of the argifin struc-
ture that are required for activity and provide the basis for the
design of new inhibitors derived from this lead, five acyclic frag-
ments of the natural product have been synthesized, inspired by
the previously published structures of argifin-chitinase com-
plexes (Houston et al., 2002b; Rao et al., 2005b). The mode of
binding of these fragments with AfChiB has been elucidated
and allowed differences in inhibitor potency observed upon
incremental structural simplification to be explained. Although
such analyses of potency changes upon systematic deconstruc-
tion of optimized synthetic inhibitors have previously been re-
ported (Hajduk, 2006), to the best of our knowledge this is the
first example of a combined kinetic and crystallographic investi-
gation of the binding of a systematically dissected natural
product.
The argifin peptide fragments can be ranked tetrapeptide >
tripeptide > dipeptide > monopeptide > dimethylguanylurea
with respect to their potencies (Table 1). This rank can be
explained by the progressive loss of protein-inhibitor contacts
observed in the crystal structures of the complexes in conjunc-Chemistry & Biology 1tion with predicted entropic penalties linked to linearization of
a conformationally restricted cyclic peptide. However, all pep-
tide fragments, including the minimal dimethylguanylurea, main-
tain a core minimum of interactions, namely the hydrogen bonds
to Asp175, Glu177 (the catalytic acid), Tyr245, and Asp246 and
stacking with Trp384. With the exception of Asp246, these
residues are conserved in family 18 chitinases throughout all
kingdoms of life. The ranking of the argifin fragments is also in
good agreement with a previously published mutagenesis study
to identify key AfChiB-argifin interactions, which showed large
effects on argifin affinity if amino acids either hydrogen bonding
to the modified argifin side chain or showing stacking inter-
actions were mutated (Rao et al., 2005b). Other known family
18 chitinase inhibitors, such as allosamidin, diketopiperazines,
and purine derivatives, also derive their potencies from interact-
ing with these active site residues (Terwisscha van Scheltinga
et al., 1994; Houston et al., 2002a; Rao et al., 2005a).
The surprising result of this study is that the pharmacophore of
the large cyclopentapeptide argifin 1 is a 9 atom fragment, the
dimethylguanylurea 6. In absolute terms, this is a poor inhibitor,
with an IC50 of 500 mMcompared to 27 nM for the natural product
(Table 1). However, viewing the same data in terms of ligand ef-
ficiency (Kuntz et al., 1999; Hopkins et al., 2004; Abad-Zapatero
and Metz, 2005), here defined as binding efficiency index (BEI)
(Abad-Zapatero and Metz, 2005), dimethylguanylurea is the
most efficient argifin fragment with a BEI of 27.7, a significantly
more efficient binder than argifin itself (BEI = 11.7 with a molecu-
lar weight of 676 Da). As evidenced by the structures of argifin-
chitinase complexes (Houston et al., 2002b; Rao et al., 2005b;
Figure 2), there are relatively large complementary buried
surfaces on the inhibitor and protein, suggesting that while not
very efficient, argifin may be a very selective inhibitor. Con-
versely, it is likely that the small dimethylguanylurea fragment
with its limited contacts will also fit a number of other active sites.5, 295–301, March 2008 ª2008 Elsevier Ltd All rights reserved 299
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Structural Dissection of ArgifinIn a given series, inhibitor potency commonly correlates with
molecular weight, and hence ligand efficiency is a more useful
measure than potency when selecting a lead compound for fur-
ther optimization into a drug or monitoring progress in a drug de-
velopment program. Recently, a retrospective analysis of several
drug discovery campaigns suggested that selecting relatively
small, efficient binders as a starting framework increases the
chances of obtaining a final optimized ligand with high potency
that does not violate the Lipinski rule-of-five (Hajduk, 2006; Lip-
inski, 2000) and fits the restrictions for acceptable absorption
and permeability properties. The dimethylguanylurea fits all
Lipinski rules, with 4 hydrogen bond donors, 1 hydrogen bond
acceptor, a molecular mass of 130 Da, and clogP =0.48. In ad-
dition, removal of all peptide bonds eliminates argifin’s intrinsic
susceptibility to proteolytic breakdown and is thus likely to give
more favorable pharmacokinetic properties. Using the observa-
tion that, in an ideal optimization program, ligand efficiency
remains constant throughout lead optimization (Hopkins et al.,
2004; Hajduk, 2006), dimethylguanylurea serves as an attractive
fragment lead with a speculative potential to be optimized to
a compound with a Ki of 60 nM at a molecule weight of 260 Da
or a Ki of 16 pM at a weight of 390 Da.
SIGNIFICANCE
Natural products are often large, non-drug-like molecules
requiring lengthy routes toward total synthesis, yet provide
useful guides for themedicinal chemist andmechanistic en-
zymologist alike. Argifin, a large natural product cyclopenta-
peptide, inhibits family 18 glycoside hydrolases (chitinases)
by extensive mimicry of protein-substrate (carbohydrate)
interactions, as shown by previous structural/mutagenesis
studies. This work shows, by cumulative truncation of the
cyclic peptide, that the majority of this 620 Da natural prod-
uct is not required for efficient inhibition. Strikingly, most of
the activity of the peptide resides in a 130Da dimethylguany-
lurea that binds deep in the active site and retains micromo-
lar inhibition. The data suggest that by rational decoration of
this natural product-derived fragment, more potent, and
drug-like, chitinase inhibitors can be obtained.
EXPERIMENTAL PROCEDURES
Expression, Purification, and Crystallization of AfChiB1
A. fumigatus chitinase B1 (AfChiB1) was overexpressed in Escherichia coli and
purified as previously described (Rao et al., 2005b). Pure enzyme was spin
concentrated to 27 mg/ml in 25 mM Tris-HCl (pH 8). The protein was crystal-
lized from 1.2 M Li2SO4, 0.1 M Tris-HCl (pH 9) using the hanging drop method.
Crystals used for soaking were washed three times in 0.1 M sodium citrate
(pH 5.5) and 1.4 M Li2SO4, with the final drop containing 1 mM inhibitor, using
2 hr of soaking time. Crystals were cryoprotected in 3 M Li2SO4 and subse-
quently flash frozen in liquid nitrogen.
Data Collection and Structural Determination of Binary
Chitinase-Peptide Complexes
X-ray diffraction data for the tetrapeptide, tripeptide, dipeptide, andmonopep-
tide complexes were collected at ID14-EH2 at the European Synchrotron
Radiation Facilities (ESRF). X-ray diffraction data for the dimethylguanylurea
complex were collected using a rotating anode. All data sets were collected
at 100 K. Processing and scaling were done using the HKL suite of programs
(Otwinowski and Minor, 1997). Cross-validation was applied by excluding 1%300 Chemistry & Biology 15, 295–301, March 2008 ª2008 Elsevier Lof the reflections throughout the refinement procedure. Rigid body and simu-
lated annealing followed by several rounds of combined refinement (energy
minimization and B-factor refinement) were performed using CNS (Brunger
et al., 1998). O (Jones et al., 1991) was used for manual adjustments of the
structures, and water molecules were included as oxygen atoms after each
round of combined refinement using appropriate criteria. Topologies for the
linear peptides were obtained using the PRODRG server (Schu¨ttelkopf and
van Aalten, 2004) and the ligands were only included when fully defined by
unbiased jFo j  jFc j, fcalc electron density maps (Figure 2). The final models
include two monomers in the asymmetric unit. In the interest of simplicity, the
structures are discussed consistently using the first monomer of the
coordinate files unless otherwise stated.
AfChiB1, hAMCase, and Lung Homogenate Enzymology
Chitinase activities for AfChiB1 (Rao et al., 2005b), hCHT (Boot et al., 1998),
and total chitinase activity in lung homogenate samples from a mouse model
of chronic asthma were determined as previously described (Schu¨ttelkopf
et al., 2006). Activities were measured in a final volume of 50 ml, and IC50 de-
terminations were done in the presence of different concentrations of inhibitor.
AfChiB1 (2 nM) was incubated with 20 mM 4-methylumbelliferyl-b-D-N-N’-
diacetylchitobiose (4MU-GlcNAc2; Sigma) and 0.25 mg/ml bovine serum
albumin in 100 mM citric acid, 200 mM Na2HPO4 (pH 5.5). hCHT (0.3 nM)
was incubated with 22 mM 4-methylumbelliferyl-b-D-N-N’-triacetylchitobiose
(4MU-GlcNAc3; Sigma) and 0.25mg/ml bovine serum albumin in 100mMcitric
acid, 200 mM Na2HPO4 (pH 5.2). Lung homogenate (39 mg/ml) (obtained as
described previously [Schu¨ttelkopf et al., 2006]) was incubated with 20 mM
4MU-GlcNAc2 in 100 mM citric acid, 200 mM Na2HPO4 (pH 5.5). All reactions
were run for 10 min at 37C, and liberated 4-methylumbelliferone (4MU) was
quantified after addition of 25 ml 3 M glycine-NaOH (pH 10.6) using an Flx
800 microtiterplate fluorescence reader (Bio-Tek instruments) with 40 nm slits
and excitation and emission wavelengths of 360 nm and 460 nm, respectively.
All experiments were performed in triplicate, and production of 4MUwas linear
for the incubation period used with less than 10% of available substrate
hydrolyzed.
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